Dr. Daver Discusses Single-Agent Immunotherapy in AML
Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses single-agent immunotherapy in acute myeloid leukemia.
Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses single-agent immunotherapy in acute myeloid leukemia (AML).
Although single agent PD-1 inhibition has not shown activity in AML, single agent CTLA-4 inhibition may have a role, says Daver. For example, promising data has been shown with ipilimumab (Yervoy) as a single agent in patients with AML.
Not all checkpoint inhibitors are equal, says Daver, and combinations will likely be the future of immunotherapy in AML.
